The International Society for Stem Cell Research (ISSCR) is proud to announce a collaboration with the Novo Nordisk ...

Indian pharma companies are challenging Novo Nordisk's semaglutide patents in court, which could pave the way for cheaper ...

As GLP-1 adoption grows and new applications for the drugs come to light, experts say that could have sweeping impacts for ...

As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

Medications are rarely made from start to finish in a single country; raw materials, active ingredients and final products often cross multiple borders before reaching patients in the U.S., The New ...

GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of ...

European collaborations are increasingly valued in a turbulent geopolitical environment. The Dutch-Danish tie-up aims to boost research, improve patient outcomes and deliver socio-economic dividends.

Williams is not the first sportsperson to promote GLP-1 weight loss medication but she is the most high profile and easily ...

Sam Bowman is an editor at Works in Progress magazine and Stripe Press. He's based in London.

Shares of Santa Monica-based prescription medication discount company GoodRx Holdings Inc. surged 37% on Aug. 18 after the ...

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...